First Trust Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-903,637
| Closed | -$36.4M | – | 2661 |
|
|
2026
Q1 | $36.4M | Buy |
903,637
+407,690
| +82% | +$8.79M | 0.03% | 710 |
|
|
2025
Q4 | $12.5M | Buy |
+495,947
| New | +$11.6M | 0.01% | 1020 |
|
|
2025
Q3 | – | Sell |
-26,538
| Closed | -$459K | – | 2576 |
|
|
2025
Q2 | $459K | Sell |
26,538
-172,671
| -87% | -$3.2M | ﹤0.01% | 2293 |
|
|
2025
Q1 | $4.36M | Buy |
199,209
+173,564
| +677% | +$4.79M | ﹤0.01% | 1388 |
|
|
2024
Q4 | $818K | Buy |
25,645
+8,344
| +48% | +$251K | ﹤0.01% | 2115 |
|
|
2024
Q3 | $499K | Sell |
17,301
-106,424
| -86% | -$3.94M | ﹤0.01% | 2170 |
|
|
2024
Q2 | $4.75M | Sell |
123,725
-282,758
| -70% | -$12.8M | ﹤0.01% | 1286 |
|
|
2024
Q1 | $23.9M | Buy |
406,483
+312,515
| +333% | +$19.9M | 0.02% | 729 |
|
|
2023
Q4 | $5.62M | Sell |
93,968
-304,170
| -76% | -$15.4M | 0.01% | 1198 |
|
|
2023
Q3 | $15.1M | Buy |
398,138
+320,847
| +415% | +$14.1M | 0.02% | 855 |
|
|
2023
Q2 | $7.04M | Buy |
77,291
+28,969
| +60% | +$2.5M | 0.01% | 1109 |
|
|
2023
Q1 | $3.19M | Sell |
48,322
-4,458
| -8% | -$257K | ﹤0.01% | 1465 |
|
|
2022
Q4 | $2.73M | Buy |
52,780
+27,551
| +109% | +$1.46M | ﹤0.01% | 1553 |
|
|
2022
Q3 | $1.72M | Sell |
25,229
-38,296
| -60% | -$2.27M | ﹤0.01% | 1754 |
|
|
2022
Q2 | $2.87M | Buy |
63,525
+5,716
| +10% | +$261K | ﹤0.01% | 1569 |
|
|
2022
Q1 | $2.94M | Buy |
+57,809
| New | +$2.55M | ﹤0.01% | 1612 |
|
|
2020
Q2 | – | Sell |
-57,356
| Closed | -$1.54M | – | 2359 |
|
|
2020
Q1 | $1.54M | Sell |
57,356
-12,772
| -18% | -$453K | ﹤0.01% | 1399 |
|
|
2019
Q4 | $2.15M | Buy |
70,128
+4,122
| +6% | +$114K | ﹤0.01% | 1520 |
|
|
2019
Q3 | $1.59M | Buy |
+66,006
| New | +$1.82M | ﹤0.01% | 1670 |
|
Other funds holding APLS
First Trust Advisors's APLS Position: Q2 2026 in Review
First Trust Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 903,637 shares — an estimated $36.4M sold.
First Trust Advisors first reported a position in APLS in Q3 2019 and held it in 19 quarters. The position peaked at $36.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- First Trust Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- First Trust Advisors sold 903,637 Apellis Pharmaceuticals shares in Q2 2026, an estimated $36.4M.
- First Trust Advisors first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 19 quarters.
- First Trust Advisors's Apellis Pharmaceuticals position peaked at $36.4M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.